University of Nebraska
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Nebraska sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).
University of Nebraska: 407 sponsored US clinical trials, 51 recruiting.
University of Nebraska sponsors 407 registered US clinical trials on ClinicalTrials.gov, 51 of them currently recruiting, and 261 completed. 31 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral Arterial Disease, with 7 trials.
Top-decile sponsor footprint
University of Nebraska ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
261 of 332 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
407 total, page 1 of 9
Parents Helping Parents for Youth Vaping Cessation
NCT07207850
Inflammation in Clear Aligners With and Without Attachments
NCT07506993
Halt Aging in Survivors of Blood Cancers
NCT07292272
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
NCT07237269
PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
NCT07234981
Detecting Peripheral Artery Disease With the Pulse
NCT07226193
Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia
NCT06364228
Does Psychotherapy Change the Gut Microbiome in Women of Child-bearing Age?
NCT07200531
Attention and Eye Movement in Parkinson's Disease
NCT06899022
Heat thErapy And mobiLity in COVID-19 Survivors
NCT06928116
Empowering Caregivers to Promote Child Independence
NCT07059364
ERAS Protocols in Breast Conserving Surgery
NCT06938581
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
NCT06799195
Validating a Blood Test for the Detection of Traumatic Brain Injury in Children
NCT06940232
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1
NCT06579196
Platelet-Rich Fibrinogen in Extraction Socket Healing of the Aged
NCT06943846
Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection
NCT06320990
SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease
NCT06480786
Effectiveness of Plaque Score Detection Techniques
NCT06511830
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease
NCT06319339
The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)
NCT06524856
Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease
NCT06389149
IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas
NCT06451341
Behavioral Economic & Staffing Strategies in the ICU
NCT06184945
The Impact of the Family Room App on Caregivers
NCT06463158
To Study the Effects of Refractive Surgery on OCT Measurements in the Eye
NCT05856786
HEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection Fraction
NCT05784753
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
NCT05903885
High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
NCT05754580
Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses
NCT05864118
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
NCT05698524
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
NCT06409949
Coagulopathy of Immunodermatologic Diseases
NCT06037187
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
NCT05269459
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
NCT05254327
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
NCT05135351
Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease (Aim 2)
NCT05070013
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
NCT04898790
Association of Periodontal Inflammation on Immune Response in Wound Healing
NCT04805320
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
NCT04799470
A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease
NCT04222062
The Influence of 3D Printed Prostheses on Neural Activation Patterns
NCT04110730
A Study Utilizing Escitalopram in Glioma Patients
NCT03728673
Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities
NCT03574207
Blood Markers of Early Pancreas Cancer
NCT03568630
Virtual Reality Augmented Gait Adaptation in Stroke Survivors
NCT03787693
Early Rheumatoid Arthritis Lung Disease Study
NCT03192267
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
NCT02842424
Integrated Cancer Repository for Cancer Research
NCT02012699
Assessment of Eloquent Function in Brain Tumor Patients
NCT01535430
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 52 |
| Phase 3 | 10 |
| Phase 4 | 21 |
Therapeutic Areas
What is open in the University of Nebraska pipeline
51 recruiting of 407 indexed (13% open); 261 completed (64%).
Phase mix: 31 late (III/IV) vs 109 early (I/II) (early-phase heavy).
Top condition: Peripheral Arterial Disease (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Nebraska: open-pipeline peers nationwide
Peers matched on 407 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 407 trials (± recruiting share)
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this University of Nebraska page
407 registered trials is a research-attention snapshot, not an endorsement of University of Nebraska or any single study.
- 51 of University of Nebraska's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Peripheral Arterial Disease is the condition University of Nebraska studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral Arterial Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Nebraska pipeline card: 407 registered trials from official public datasets.Report a data error.